Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 66


Strategies for clinical implementation of TNM-immunoscore in resected non-small cell lung cancer.

Donnem T, Kilvaer TK, Andersen S, Richardsen E, Paulsen E, Hald SM, Al-Saad S, Brustugun OT, Helland A, Lund-Iversen M, Solberg S, Gronberg BH, Wahl SG, Helgeland L, Fløtten O, Pohl M, Al-Shibli K, Sandanger TM, Pezzella F, Busund L, Bremnes RM.

Ann Oncol. 2015 Nov 16. pii: mdv560. [Epub ahead of print] Review.


Lymphangiogenic Markers and Their Impact on Nodal Metastasis and Survival in Non-Small Cell Lung Cancer - A Structured Review with Meta-Analysis.

Kilvaer TK, Paulsen EE, Hald SM, Wilsgaard T, Bremnes RM, Busund LT, Donnem T.

PLoS One. 2015 Aug 25;10(8):e0132481. doi: 10.1371/journal.pone.0132481. eCollection 2015.


The Prognostic Significance of CXCL16 and Its Receptor C-X-C Chemokine Receptor 6 in Prostate Cancer.

Richardsen E, Ness N, Melbø-Jørgensen C, Johannesen C, Grindstad T, Nordbakken C, Al-Saad S, Andersen S, Dønnem T, Nordby Y, Bremnes RM, Busund LT.

Am J Pathol. 2015 Oct;185(10):2722-30. doi: 10.1016/j.ajpath.2015.06.013. Epub 2015 Aug 10.


Stromal expression of VEGF-A and VEGFR-2 in prostate tissue is associated with biochemical and clinical recurrence after radical prostatectomy.

Nordby Y, Andersen S, Richardsen E, Ness N, Al-Saad S, Melbø-Jørgensen C, Patel HR, Dønnem T, Busund LT, Bremnes RM.

Prostate. 2015 Nov;75(15):1682-93. doi: 10.1002/pros.23048. Epub 2015 Aug 13.


Cancer Associated Fibroblasts in Stage I-IIIA NSCLC: Prognostic Impact and Their Correlations with Tumor Molecular Markers.

Kilvaer TK, Khanehkenari MR, Hellevik T, Al-Saad S, Paulsen EE, Bremnes RM, Busund LT, Donnem T, Martinez IZ.

PLoS One. 2015 Aug 7;10(8):e0134965. doi: 10.1371/journal.pone.0134965. eCollection 2015.


Organized metabolic crime in prostate cancer: The coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure.

Andersen S, Solstad Ø, Moi L, Donnem T, Eilertsen M, Nordby Y, Ness N, Richardsen E, Busund LT, Bremnes RM.

Urol Oncol. 2015 Aug;33(8):338.e9-17. doi: 10.1016/j.urolonc.2015.05.013. Epub 2015 Jun 8.


Keratin 34betaE12/keratin7 expression is a prognostic factor of cancer-specific and overall survival in patients with early stage non-small cell lung cancer.

Pøhl M, Olsen KE, Holst R, Donnem T, Busund LT, Bremnes RM, Al-Saad S, Andersen S, Richardsen E, Ditzel HJ, Hansen O.

Acta Oncol. 2015 Jun 9:1-11. [Epub ahead of print]


Prognostic impact of CXCL16 and CXCR6 in non-small cell lung cancer: combined high CXCL16 expression in tumor stroma and cancer cells yields improved survival.

Hald SM, Kiselev Y, Al-Saad S, Richardsen E, Johannessen C, Eilertsen M, Kilvaer TK, Al-Shibli K, Andersen S, Busund LT, Bremnes RM, Donnem T.

BMC Cancer. 2015 May 29;15:441. doi: 10.1186/s12885-015-1446-z.


High progesterone receptor expression in prostate cancer is associated with clinical failure.

Grindstad T, Andersen S, Al-Saad S, Donnem T, Kiselev Y, Nordahl Melbø-Jørgensen C, Skjefstad K, Busund LT, Bremnes RM, Richardsen E.

PLoS One. 2015 Feb 27;10(2):e0116691. doi: 10.1371/journal.pone.0116691. eCollection 2015.


Stromal CD8+ T-cell Density—A Promising Supplement to TNM Staging in Non-Small Cell Lung Cancer.

Donnem T, Hald SM, Paulsen EE, Richardsen E, Al-Saad S, Kilvaer TK, Brustugun OT, Helland A, Lund-Iversen M, Poehl M, Olsen KE, Ditzel HJ, Hansen O, Al-Shibli K, Kiselev Y, Sandanger TM, Andersen S, Pezzella F, Bremnes RM, Busund LT.

Clin Cancer Res. 2015 Jun 1;21(11):2635-43. doi: 10.1158/1078-0432.CCR-14-1905. Epub 2015 Feb 13.


The prognostic role of progesterone receptor expression in non-small cell lung cancer patients: Gender-related impacts and correlation with disease-specific survival.

Skjefstad K, Richardsen E, Donnem T, Andersen S, Kiselev Y, Grindstad T, Hald SM, Al-Shibli K, Bremnes RM, Busund LT, Al-Saad S.

Steroids. 2015 Jun;98:29-36. doi: 10.1016/j.steroids.2015.01.020. Epub 2015 Feb 7.


Stromal expression of MiR-21 predicts biochemical failure in prostate cancer patients with Gleason score 6.

Melbø-Jørgensen C, Ness N, Andersen S, Valkov A, Dønnem T, Al-Saad S, Kiselev Y, Berg T, Nordby Y, Bremnes RM, Busund LT, Richardsen E.

PLoS One. 2014 Nov 17;9(11):e113039. doi: 10.1371/journal.pone.0113039. eCollection 2014.


Monocarboxylate transporters 1-4 in NSCLC: MCT1 is an independent prognostic marker for survival.

Eilertsen M, Andersen S, Al-Saad S, Kiselev Y, Donnem T, Stenvold H, Pettersen I, Al-Shibli K, Richardsen E, Busund LT, Bremnes RM.

PLoS One. 2014 Sep 16;9(9):e105038. doi: 10.1371/journal.pone.0105038. eCollection 2014.


Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer.

Ness N, Andersen S, Valkov A, Nordby Y, Donnem T, Al-Saad S, Busund LT, Bremnes RM, Richardsen E.

Prostate. 2014 Oct;74(14):1452-61. doi: 10.1002/pros.22862. Epub 2014 Aug 11.


Disease-specific outcomes of radical prostatectomies in Northern Norway; a case for the impact of perineural infiltration and postoperative PSA-doubling time.

Andersen S, Richardsen E, Nordby Y, Ness N, Størkersen O, Al-Shibli K, Donnem T, Bertilsson H, Busund LT, Angelsen A, Bremnes RM.

BMC Urol. 2014 Jun 14;14:49. doi: 10.1186/1471-2490-14-49.


Stage and tissue-specific prognostic impact of miR-182 in NSCLC.

Stenvold H, Donnem T, Andersen S, Al-Saad S, Busund LT, Bremnes RM.

BMC Cancer. 2014 Feb 27;14:138. doi: 10.1186/1471-2407-14-138.


High tumor cell expression of microRNA-21 in node positive non-small cell lung cancer predicts a favorable clinical outcome.

Stenvold H, Donnem T, Andersen S, Al-Saad S, Valkov A, Pedersen MI, Busund LT, Bremnes RM.

BMC Clin Pathol. 2014 Feb 13;14(1):9. doi: 10.1186/1472-6890-14-9.


The VEGF- and PDGF-family of angiogenic markers have prognostic impact in soft tissue sarcomas arising in the extremities and trunk.

Kilvaer TK, Smeland E, Valkov A, Sorbye SW, Bremnes RM, Busund LT, Donnem T.

BMC Clin Pathol. 2014 Jan 20;14(1):5. doi: 10.1186/1472-6890-14-5.


Positive prognostic impact of miR-210 in non-small cell lung cancer.

Eilertsen M, Andersen S, Al-Saad S, Richardsen E, Stenvold H, Hald SM, Al-Shibli K, Donnem T, Busund LT, Bremnes RM.

Lung Cancer. 2014 Feb;83(2):272-8. doi: 10.1016/j.lungcan.2013.11.005. Epub 2013 Nov 14.


Vessel co-option in primary human tumors and metastases: an obstacle to effective anti-angiogenic treatment?

Donnem T, Hu J, Ferguson M, Adighibe O, Snell C, Harris AL, Gatter KC, Pezzella F.

Cancer Med. 2013 Aug;2(4):427-36. doi: 10.1002/cam4.105. Epub 2013 Jul 8. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk